Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Withdraws Direct-To-Consumer Ad Guidance, As It Develops Social Media Documents

This article was originally published in The Gray Sheet

Executive Summary

Agency reps updated stakeholders on guidance development efforts related to advertising and promotion during a Food and Drug Law Institute conference in Washington, D.C.


Related Content

CDRH To Beef Up Monitoring Of Device Ads And Promotions
FDA Subject To More Oversight Following User Fee Bill Passage
Off-Label Questions, Online: FDA Explains How To Handle Them
DTC Guidances Need Added Focus On Device-Specific Issues – AdvaMed





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts